Pulmonary arterial hypertension has a poor prognosis quoad vitam et valitudinem. Herein, we report on a middle-aged woman affected by idiopathic pulmonary arterial hypertension whose quality of life and exercise tolerance improved remarkably after a six-month course of treatment with the long-acting phosphodiesterase-5 inhibitor tadalafil
Background: Phosphodiesterase-5 (PDE5) inhibitors improve exercise capacity and quality of life in p...
Pulmonary arterial hypertension (PAH) is a rare and progressive disease of the pulmonary arterial ci...
AbstractPulmonary arterial hypertension is defined as a group of diseases characterized by a progres...
Pulmonary arterial hypertension has a poor prognosis quoad vitam et valitudinem. Herein, we report o...
Treatment options for pulmonary arterial hypertension target the prostacyclin, endothelin, or nitric...
BACKGROUND: Treatment options for pulmonary arterial hypertension target the prostacyclin, endotheli...
We report the long-term follow-up of 3 cases of severe idiopathic pulmonary arterial hypertension, i...
Background: Sildenafil, a short-acting phosphodiesterase-5 inhibitor (1), is safe and may benefit pa...
ObjectivesThe aim of this study was to evaluate the long-term safety and durability of efficacy of t...
Background The primary objective of this post hoc analysis was to evaluate clinical outcomes of tada...
The pathology of pulmonary arterial hypertension (PAH) is characterized by vascular vasoconstriction...
Objective: The objective of this systematic review is to determine whether or not the oral Phosphodi...
Introduction: Two phosphodiesterase-type 5 (PDE-5) inhibitors, sildenafil and tadalafil, are approve...
Pulmonary arterial hypertension (PAH) secondary to chronic obstructive pulmonary disease (COPD) is i...
Background and objective Interstitial lung diseases (ILD) are often associated with pulmonary hypert...
Background: Phosphodiesterase-5 (PDE5) inhibitors improve exercise capacity and quality of life in p...
Pulmonary arterial hypertension (PAH) is a rare and progressive disease of the pulmonary arterial ci...
AbstractPulmonary arterial hypertension is defined as a group of diseases characterized by a progres...
Pulmonary arterial hypertension has a poor prognosis quoad vitam et valitudinem. Herein, we report o...
Treatment options for pulmonary arterial hypertension target the prostacyclin, endothelin, or nitric...
BACKGROUND: Treatment options for pulmonary arterial hypertension target the prostacyclin, endotheli...
We report the long-term follow-up of 3 cases of severe idiopathic pulmonary arterial hypertension, i...
Background: Sildenafil, a short-acting phosphodiesterase-5 inhibitor (1), is safe and may benefit pa...
ObjectivesThe aim of this study was to evaluate the long-term safety and durability of efficacy of t...
Background The primary objective of this post hoc analysis was to evaluate clinical outcomes of tada...
The pathology of pulmonary arterial hypertension (PAH) is characterized by vascular vasoconstriction...
Objective: The objective of this systematic review is to determine whether or not the oral Phosphodi...
Introduction: Two phosphodiesterase-type 5 (PDE-5) inhibitors, sildenafil and tadalafil, are approve...
Pulmonary arterial hypertension (PAH) secondary to chronic obstructive pulmonary disease (COPD) is i...
Background and objective Interstitial lung diseases (ILD) are often associated with pulmonary hypert...
Background: Phosphodiesterase-5 (PDE5) inhibitors improve exercise capacity and quality of life in p...
Pulmonary arterial hypertension (PAH) is a rare and progressive disease of the pulmonary arterial ci...
AbstractPulmonary arterial hypertension is defined as a group of diseases characterized by a progres...